✦ LIBER ✦

PAR6 COST-UTILITY ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS PATIENTS IN CANADA

✍ Scribed by B Mistry; J McCormick; A Diamantopoulos; A Kielhorn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PAR4 COST-EFFECTIVENESS ANALYSIS OF RITU

✍ D Porter; G Lewis; B Brown; A Diamantopoulos; A Kielhorn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PAR5 COST-EFFECTIVENESS OF RITUXIMAB AS

✍ A Rubbert; A Kielhorn; S Schach; B Brown 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PAR23 COST-UTILITY OF ABATACEPT, A NEW B

✍ NS Hawkins; K Minda; D Parry; P Hines; Y Yuan; R Maclean 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PAR14 COST MINIMIZATION ANALYSIS OF RITU

✍ MG Saggia; EA Santos; V Nasciben 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

UK cost-utility analysis of rituximab in

✍ Kielhorn, Adrian; Porter, Duncan; Diamantopoulos, Alexander; Lewis, Gavin 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 147 KB

PAR13 A PROSPECTIVE STUDY COMPARING DRUG

✍ TP Meleth; J Varkey; J Philip; L Lai 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB